Zynex, Inc. (NASDAQ:ZYXI) Q3 2023 Earnings Conference Call October 26, 2023 4:15 PM ET
Company Participants
Quinn Callanan - Investor Relations
Thomas Sandgaard - Chairman, President and Chief Executive Officer
Anna Lucsok - Chief Operating Officer
Donald Gregg - Vice President, Zynex Monitoring Solutions
Daniel Moorhead - Chief Financial Officer
Conference Call Participants
Jeffrey Cohen - Ladenburg Thalmann
Shagun Singh Chadha - RBC
Yi Chen - H.C. Wainwright
Operator
Good day ladies and gentlemen, and welcome to the Zynex Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
I would now like to turn the conference over to Quinn Callanan from MZ North America.
Quinn Callanan
Thank you, operator and good afternoon everyone. Earlier today, Zynex released financial results for the third quarter ending September 30, 2023. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Sandgaard, Chairman, President and Chief Executive Officer; Dan Moorhead, Chief Financial Officer; Anna Lucsok, Chief Operating Officer; and Donald Gregg, President of Zynex Monitoring Solutions.
Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation, the company's 2022 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance.
With that, I'll now turn the call over to Thomas.
Thomas Sandgaard
Thanks Quinn and good afternoon everyone. Thank you for joining us today for our third quarter 2023 earnings call. The third quarter was highlighted by ongoing revenue momentum leading us to our 10th consecutive quarter of profitability and sixth quarter of record high order numbers.
We've once again received the highest number of prescriptions in the company's history beating our previous record and celebrated our 1 millionth patient treated since I founded Zynex. These records led to total revenue for the quarter of $49.9 million, a 20% increase over the same period in 2022 and we produced $0.10 of earnings per diluted share.